Reference health
PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis
23/23 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
2 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 23 checked references that resolve
resolves10.1186/s40425-019-0636-7
Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials
resolves10.1093/annonc/mdp149
Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
resolves10.1186/s40425-019-0662-5
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
resolves10.1016/j.ejca.2004.05.019
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer
resolves10.1200/JCO.2016.70.1524
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
resolves10.1016/S0140-6736(18)31999-8
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
resolves10.1007/s12026-012-8306-6
Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer
resolves10.1016/j.ejca.2018.12.029
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
resolves10.1056/NEJMoa1200690
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
resolves10.1016/j.oraloncology.2018.04.008
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
resolves10.1093/annonc/mdy411
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
resolves10.1001/jamaoncol.2018.4628
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
resolves10.1016/S0140-6736(19)32591-7
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
resolves10.1016/j.annonc.2020.04.001
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
resolves10.1097/MD.0000000000024339
Anti-PD1/PD-L1 monotherapy vs standard of care in patients with recurrent or metastatic head and neck squamous cell carcinoma
resolves10.2217/imt-2017-0153
Do Immune Checkpoint Inhibitors Increase Sensitivity to Salvage Chemotherapy?
resolves10.1001/jamaoto.2021.2191
Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer
resolves10.1016/S0140-6736(18)32409-7
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The 2 references without a DOI — listed, not checked
no DOI — not checkedGlobal cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
no DOI — not checkedCochrane bias methods group; Cochrane statistical methods group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/j.amjoto.2021.103324"><img src="https://citestamp.com/citestamped/10.1016/j.amjoto.2021.103324/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1016/j.amjoto.2021.103324)